Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | THRA | P10827 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7799131 | 0.96 | PDK2 (0.36) | PDK2HSP90AA1 | |
| SCHEMBL8531070 | 0.89 | MEN1 (0.31) | — | |
| SCHEMBL7801055 | 0.87 | HPGD (0.39) | — | |
| SCHEMBL7793516 | 0.86 | BCHE (0.34) | PDK2THRAHDAC6TRPV1 | |
| SCHEMBL8437417 | 0.85 | HCAR3 (0.33) | — | |
| SCHEMBL7799355 | 0.84 | HPGD (0.34) | HSP90AA1 | |
| SCHEMBL7799119 | 0.84 | MEN1 (0.43) | HDAC6 | |
| SCHEMBL7802386 | 0.81 | KMT2A (0.40) | — | |
| SCHEMBL7793529 | 0.79 | RIPK1 (0.37) | — | |
| SCHEMBL7801041 | 0.73 | TSHR (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010001101-A1 | Phenanthroline derivatives | ZENECA LIMITED | 2001-05-10 | — | — | US | disclosed |
| EP-1027351-A1 | PHENANTHROLINE DERIVATIVES | FIBROGEN, INC. (US) | 2000-08-16 | — | — | EP | disclosed |
| US-5916898-A | ANTIFIBROPROLIFERTIVE, ENZYME INHIBITORS OF PYROLYL 4-HYDROXYLASE, ANTIARTHRITIC AGENTS | ZENECA LIMITED (GB) | 1999-06-29 | — | — | US | disclosed |
| WO-1999021860-A1 | PHENANTHROLINE DERIVATIVES | FIBROGEN, INC. (US) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010001101-A1 | Phenanthroline derivatives | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, COL1A1, COL2A1 | PDK2 4076/4885THRA 4414/4885HDAC6 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.